Immune checkpoint inhibitor (ICI) therapies have ushered in an exciting new phase of clinical research and treatment for malignant pleural mesothelioma (MPM), offering more effective and less toxic treatment options for patients. The research and clinical oncology communities eagerly await the completion of several upcoming trials focused on … [Read more...]
Nivolumab plus ipilimumab confers sustained OS benefit in malignant pleural mesothelioma
Nivolumab plus ipilimumab conferred a durable survival benefit compared with chemotherapy as first-line treatment for unresectable malignant pleural mesothelioma, according to randomized phase 3 trial data released by the manufacturer. The open-label, multicenter CheckMate-743 trial included 605 patients who received six cycles of pemetrexed and … [Read more...]
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
INCIDENCE AND EPIDEMIOLOGY Incidence Incidence of malignant pleural mesothelioma (MPM) is generally higher in males than females and is attributed to historical differences in [ asbestos exposure ] with world-standardised incidence rates per 100,000 persons of 0.7 and 0.3 in the USA and 1.7 and 0.4 for Europe (for males and females, … [Read more...]
Imfinzi-Chemo Combo Improves Survival for Mesothelioma
Imfinzi plus platinum-pemetrexed chemotherapy induced survival improvements in patients with previously untreated, unresectable malignant pleural mesothelioma, compared with chemotherapy alone. Treatment with Imfinzi (durvalumab) plus platinum-pemetrexed chemotherapy was associated with improved survival among patients with previously untreated, … [Read more...]
Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
Background: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab [(Opdivo)], an anti-PD-1 antibody, in these patients. Methods: This was a multicentre, … [Read more...]
Immunotherapy combination maintains OS advantage in malignant pleural mesothelioma
The combination of [ Opdivo and Yervoy ] maintained its survival advantage over chemotherapy with at least 3 years of follow-up among patients with unresectable malignant pleural mesothelioma, according to CheckMate 743 study results. Researchers observed the benefit of the first-line immunotherapy regimen despite patients having been off … [Read more...]
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
Background: There is a preclinical rationale for inhibiting angiogenesis in mesothelioma. We aimed to assess the efficacy and safety of the anti-VEGFR-2 antibody ramucirumab combined with gemcitabine in patients with pretreated malignant pleural mesothelioma [ as a second-line treatment ]. Methods: RAMES was a multicentre, randomised, … [Read more...]
Adding Atezolizumab to Neoadjuvant Cisplatin-Pemetrexed a Feasible Option in Malignant Pleural Mesothelioma
A three-agent neoadjuvant regimen that combines a PD-L1 inhibitor with chemotherapy appears feasible for patients with malignant pleural mesothelioma, according to an ongoing phase I trial. The findings [ about neoadjuvant therapy ] were presented at the International Association for the Study of Lung Cancer virtual World Conference on Lung Cancer, … [Read more...]
Nivo/Ipi Combo Now ‘Standard of Care’ in Mesothelioma
The [ combination immunotherapy consisting ] of nivolumab (Opdivo) and ipilimumab (Yervoy) offers a durable, long-term survival benefit over chemotherapy for patients with unresectable malignant pleural mesothelioma (MPM), confirms a 3-year updated analysis of the CheckMate 743 trial. After 3 years, 23% of patients who received combination … [Read more...]